GlassScriptPhysician profile
Inna Kremen
NPI 1588039846
$1,437.55
in general payments reported to CMS, 2019-2025
14 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.54 · 2022: $682 · 2023: $213 · 2024: $65.86 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.57 | 2021-2025 | |
| Exeltis, USA INC. | $152.96 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $139.22 | 2021-2025 | |
| Astellas Pharma US INC | $133.37 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $120.08 | 2021-2025 | |
| Evofem Biosciences, INC. | $113.60 | 2021-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $83.53 | 2022-2025 | Jada System, Nexplanon |
| Millicent US INC | $70.91 | 2025 | Femlyv, Intrarosa |
| Avion Pharmaceuticals | $28.74 | 2022-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $28.02 | 2024 | Aptima |
| Sumitomo Pharma America, INC. | $18.93 | 2025 | Myfembree |
| Coopersurgical, INC. | $17.33 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $15.86 | 2023 | Vivjoa |
| Biohaven Pharmaceutical Holding Company LTD. | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Kremen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.